SLGL — Sol-Gel Technologies Ltd.
$55.12
$-1.13 (-2.01%)
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Market Cap
$180.46M
Forward P/E
-6.9x
52-Week Range
N/A
SLGL Price History
Revenue vs. Net Income
$19.4M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$275K
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-31.7%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
4.2x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.2%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+0.0%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
